Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Prof Umberto Vitolo, MDa Send email to umberto.vitolo@ircc.it ∙ Juan Miguel Bergua Burgues, MDb ∙ Johannes Duell, MDc ∙ Michal Kwiatek, MDd ∙ David Belada, MD PhDe ∙ Wojciech Jurczak, MD PhDf ∙ et al.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Prof Umberto Vitolo, MDa Send email to umberto.vitolo@ircc.it ∙ Juan Miguel Bergua Burgues, MDb ∙ Johannes Duell, MDc ∙ Michal Kwiatek, MDd ∙ David Belada, MD PhDe ∙ Wojciech Jurczak, MD PhDf ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00112-2/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-9FnJ5j5Y6Y-nDJsIE9y3t_mYxrsI9cVpsk2TSB-EgXrObaDC0p8hSZ5eksJX5NUke7pQxmH1CpDAAahWPm1eOSV1gPZQ&_hsmi=428051533&utm_content=427687149&utm_source=hs_email